{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:58:20Z","timestamp":1794373100742,"version":"4.9.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA175491"],"award-info":[{"award-number":["R01 CA175491"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA244948"],"award-info":[{"award-number":["R01 CA244948"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA92629"],"award-info":[{"award-number":["P50 CA92629"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100000052","name":"U.S. Department of Health & Human Services | NIH | NIH Office of the Director","doi-asserted-by":"publisher","award":["S10 OD018522"],"award-info":[{"award-number":["S10 OD018522"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"U.S. Department of Health & Human Services | NIH | NIH Office of the Director","doi-asserted-by":"publisher","award":["S10 OD026880"],"award-info":[{"award-number":["S10 OD026880"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | NIH Office of the Director"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 2017\/559"],"award-info":[{"award-number":["CAN 2017\/559"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2016-02974"],"award-info":[{"award-number":["2016-02974"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"General Hospital in Malm\u00f6 Foundation for Combating Cancer Sidney Kimmel Center for Prostate and Urologic Cancers"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polygenic risk scores (PRS) for prostate cancer incidence have been proposed to optimize prostate cancer screening. Prediction of lethal prostate cancer is key to any stratified screening program to avoid excessive overdiagnosis. Herein, PRS for incident prostate cancer was evaluated in two population-based cohorts of unscreened middle-aged men linked to cancer and death registries: the V\u00e4sterbotten Intervention Project (VIP) and the Malm\u00f6 Diet and Cancer study (MDC). SNP genotypes were measured by genome-wide SNP genotyping by array followed by imputation or genotyping of selected SNPs using mass spectrometry. The ability of PRS to predict lethal prostate cancer was compared to PSA and a commercialized pre-specified model based on four kallikrein markers. The PRS was associated with incident prostate cancer, replicating previously reported relative risks, and was also associated with prostate cancer death. However, unlike PSA, the PRS did not show stronger association with lethal disease: the hazard ratio for prostate cancer incidence vs. prostate cancer metastasis and death was 1.69 vs. 1.65 in VIP and 1.25 vs. 1.25 in MDC. PSA was a much stronger predictor of prostate cancer metastasis or death with an area-under-the-curve of 0.78 versus 0.63 for the PRS. Importantly, addition of PRS to PSA did not contribute additional risk stratification for lethal prostate cancer. We have shown that a PRS that predicts prostate cancer incidence does not have utility above and beyond that of PSA measured at baseline when applied to the clinically relevant endpoint of prostate cancer death. These findings have implications for public health policies for delivery of prostate cancer screening. Focusing polygenic risk scores on clinically significant endpoints such as prostate cancer metastasis or death would likely improve clinical utility.<\/jats:p>","DOI":"10.1038\/s41698-022-00266-8","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T10:11:21Z","timestamp":1649412681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Prostate cancer polygenic risk score and prediction of lethal prostate cancer"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-5391","authenticated-orcid":false,"given":"Robert J.","family":"Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6948-9850","authenticated-orcid":false,"given":"Emily","family":"Vertosick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Sjoberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ulmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2493-3142","authenticated-orcid":false,"given":"Ann-Charlotte","family":"R\u00f6nn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"H\u00e4ggstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Thysell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"Hallmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Dahlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Stattin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Melander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-7846","authenticated-orcid":false,"given":"Hans","family":"Lilja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"266_CR1","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41588-018-0142-8","volume":"50","author":"FR Schumacher","year":"2018","unstructured":"Schumacher, F. R. et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat. Genet. 50, 928\u2013936 (2018).","journal-title":"Nat. Genet."},{"key":"266_CR2","doi-asserted-by":"publisher","first-page":"j5757","DOI":"10.1136\/bmj.j5757","volume":"360","author":"TM Seibert","year":"2018","unstructured":"Seibert, T. M. et al. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ 360, j5757 (2018).","journal-title":"BMJ"},{"key":"266_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41591-020-0800-0","volume":"26","author":"N Mars","year":"2020","unstructured":"Mars, N. et al. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. Nat. Med. 26, 549\u2013557 (2020).","journal-title":"Nat. Med."},{"key":"266_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.eururo.2020.11.014","volume":"79","author":"Z Shi","year":"2020","unstructured":"Shi, Z. et al. Performance of three inherited risk measures for predicting prostate cancer incidence and mortality: a population-based prospective analysis. Eur. Urol. 79, 419\u2013426 (2020).","journal-title":"Eur. Urol."},{"key":"266_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19600-4","volume":"11","author":"L Kachuri","year":"2020","unstructured":"Kachuri, L. et al. Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction. Nat. Commun. 11, 6084 (2020).","journal-title":"Nat. Commun."},{"key":"266_CR6","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1002\/ijc.29538","volume":"137","author":"KJL Bell","year":"2015","unstructured":"Bell, K. J. L., Del Mar, C., Wright, G., Dickinson, J. & Glasziou, P. Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int. J. Cancer 137, 1749\u20131757 (2015).","journal-title":"Int. J. Cancer"},{"key":"266_CR7","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/jnci\/djp278","volume":"101","author":"HG Welch","year":"2009","unstructured":"Welch, H. G. & Albertsen, P. C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J. Natl Cancer Inst. 101, 1325\u20131329 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"266_CR8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.eururo.2018.02.016","volume":"73","author":"DD Sjoberg","year":"2018","unstructured":"Sjoberg, D. D. et al. Twenty-year risk of prostate cancer death by midlife prostate-specific antigen and a panel of four kallikrein markers in a large population-based cohort of healthy men. Eur. Urol. 73, 941\u2013948 (2018).","journal-title":"Eur. Urol."},{"key":"266_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/JU.0000000000001007","volume":"204","author":"EA Vertosick","year":"2020","unstructured":"Vertosick, E. A. et al. Prespecified 4 kallikrein marker model (4Kscore) at age 50 or 60 for early detection of lethal prostate cancer in a large population based cohort of asymptomatic men followed for 20 years. J. Urol. 204, 281\u2013288 (2020).","journal-title":"J. Urol."},{"key":"266_CR10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","volume":"68","author":"DJ Parekh","year":"2015","unstructured":"Parekh, D. J. et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur. Urol. 68, 464\u2013470 (2015).","journal-title":"Eur. Urol."},{"key":"266_CR11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.eururo.2018.06.021","volume":"74","author":"W Li","year":"2018","unstructured":"Li, W. et al. Genome-wide scan identifies role for AOX1 in prostate cancer survival. Eur. Urol. 74, 710\u2013719 (2018).","journal-title":"Eur. Urol."},{"key":"266_CR12","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ajhg.2020.08.025","volume":"107","author":"LG Fritsche","year":"2020","unstructured":"Fritsche, L. G. et al. Cancer PRSweb: an online repository with polygenic risk scores for major cancer traits and their evaluation in two independent biobanks. Am. J. Hum. Genet. 107, 815\u2013836 (2020).","journal-title":"Am. J. Hum. Genet."},{"key":"266_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21288-z","volume":"12","author":"RE Graff","year":"2021","unstructured":"Graff, R. E. et al. Cross-cancer evaluation of polygenic risk scores for 16 cancer types in two large cohorts. Nat. Commun. 12, 970 (2021).","journal-title":"Nat. Commun."},{"key":"266_CR14","doi-asserted-by":"crossref","unstructured":"Vickers, A. J. et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 346, https:\/\/www.bmj.com\/content\/346\/bmj.f2023 (2013).","DOI":"10.1136\/bmj.f2023"},{"key":"266_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.urology.2015.12.054","volume":"91","author":"AJ Vickers","year":"2016","unstructured":"Vickers, A. J., Eastham, J. A., Scardino, P. T. & Lilja, H. The Memorial Sloan Kettering Cancer Center recommendations for prostate cancer screening. Urology 91, 12\u201318 (2016).","journal-title":"Urology"},{"key":"266_CR16","doi-asserted-by":"publisher","first-page":"e1002998","DOI":"10.1371\/journal.pmed.1002998","volume":"16","author":"T Callender","year":"2019","unstructured":"Callender, T. et al. Polygenic risk-tailored screening for prostate cancer: a benefit-harm and cost-effectiveness modelling study. PLoS Med. 16, e1002998 (2019).","journal-title":"PLoS Med."},{"key":"266_CR17","doi-asserted-by":"crossref","unstructured":"Benafif, S. et al. The BARCODE1 pilot: a feasibility study of using germline SNPs to target prostate cancer screening. BJU Int. 129, 325\u2013336 (2022).","DOI":"10.1111\/bju.15535"},{"key":"266_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard, C. C. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375, 443\u2013453 (2016).","journal-title":"N. Engl. J. Med."},{"key":"266_CR19","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-018-0183-z","volume":"50","author":"AV Khera","year":"2018","unstructured":"Khera, A. V. et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 50, 1219\u20131224 (2018).","journal-title":"Nat. Genet."},{"key":"266_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2015.01.009","volume":"68","author":"P Stattin","year":"2015","unstructured":"Stattin, P. et al. Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study. Eur. Urol. 68, 207\u2013213 (2015).","journal-title":"Eur. Urol."},{"key":"266_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/jnci\/djs486","volume":"105","author":"CA Haiman","year":"2013","unstructured":"Haiman, C. A. et al. Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations. J. Natl Cancer Inst. 105, 237\u2013243 (2013).","journal-title":"J. Natl Cancer Inst."},{"key":"266_CR22","doi-asserted-by":"publisher","first-page":"7809","DOI":"10.1021\/ac061201+","volume":"78","author":"V V\u00e4is\u00e4nen","year":"2006","unstructured":"V\u00e4is\u00e4nen, V., Peltola, M. T., Lilja, H., Nurmi, M. & Pettersson, K. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab\u2019)2 fragments. Anal. Chem. 78, 7809\u20137815 (2006).","journal-title":"Anal. Chem."},{"key":"266_CR23","doi-asserted-by":"crossref","unstructured":"Lambert, S. A. et al. The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation. Nat. Genet. 53, 420\u2013425 (2021).","DOI":"10.1038\/s41588-021-00783-5"},{"key":"266_CR24","doi-asserted-by":"publisher","first-page":"djv095","DOI":"10.1093\/jnci\/djv095","volume":"107","author":"RJ Bryant","year":"2015","unstructured":"Bryant, R. J. et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J. Natl Cancer Inst. 107, djv095 (2015).","journal-title":"J. Natl Cancer Inst."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00266-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00266-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00266-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T08:00:29Z","timestamp":1669363229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00266-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["266"],"URL":"https:\/\/doi.org\/10.1038\/s41698-022-00266-8","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"assertion":[{"value":"26 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.L. is named on a patent for intact PSA assays. A.V. and H.L. are named on a patent for a statistical method to detect prostate cancer that has been licensed to and commercialized by OPKO Health. They both receive royalties from sales of the test. A.V. has stock options and H.L. has stock in OPKO Health. No other authors have any competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}